Brought to you by 
Receptos nets $68.3mm through its IPO
22 Dec 2020
Executive Summary
Receptos Inc. (immune and metabolic disease therapeutics) has netted $68.3mm through its initial public offering of 5.2mm common shares at $14, the low end of its proposed terms. (Last month the company announced intentions to sell 4.7mm shares between $14-16.)
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Genomics-Proteomics
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Receptos nets $68.3mm through its IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice